Benzinga | Apr 29, 2021 12:12PM EDT

Chardan Capital Downgrades Adverum Biotechnologies to Neutral, Lowers Price Target to $5

Chardan Capital analyst Gbola Amusa downgrades Adverum Biotechnologies (NASDAQ:ADVM) from Buy to Neutral and lowers the price target from $20 to $5.